Key Takeaways
- Today, Nourish published data on GLP-1 medication persistence for patients in our program, examining the impact of integrated nutrition and lifestyle support on patients' ability to stay on medication long enough to see results.
- This data shows that 68% of Nourish patients are persistent at 6 months, meaningfully outperforming a 46% industry benchmark.
- This strong persistence data is a signal that integrated, dietitian-led care plays an important role in closing the persistence gap and ultimately helping patients realize the long-term benefits of GLP-1s.
GLP-1 medications have emerged as a powerful tool for patients managing obesity and metabolic disease, and their rapid adoption is reshaping the landscape of care. Despite this promise, a critical challenge remains when it comes to persistence. Most patients don't stay on these medications long enough to see their full clinical benefit. Real-world evidence shows fewer than half of patients are still on a GLP-1 at six months, and those who discontinue often regain a significant portion of the weight they lost.
At Nourish, our care model tackles this persistence gap directly. Our dietitian-led approach pairs GLP-1 therapy with personalized nutrition support at every stage of a patient's medication journey, addressing the clinical and lifestyle barriers that can result in patients stopping treatment prematurely.
We're excited to share data that indicates this model is working. For Nourish patients on GLP-1s, our outcomes show 68% persistence at six months, compared to a 46% industry benchmark. This data represents a meaningful signal that integrated, nutrition-first care can improve GLP-1 outcomes at scale.
Read the full whitepaper here.
Do you have any of these insurances?
Why Join Nourish's RD Network
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
